Abstract:
Diabetes Mellitus is one of the major causes of renal impairment and a major public health
problem globally. Diabetes is associated with microvascular complications that also includes
nephropathy. Diabetes nephropathy is the leading cause of renal failure in such patients.
Diabetes Mellitus is one of the major causes of renal impairment and a major public health
problem globally. Adequate glycemic control is essential to prevent or delay the onset of
diabetic nephropathy. There are availability of antidiabetic medications in the market. However,
only a few can be used safely in patients suffering from both diabetes and chronic kidney
disease. Metformin has been recommended as the first line antidiabetic drug recommended by
the American Diabetes Association. If a single agent is failed to achieve adequate glucose
control, a combination oral antidiabetics may result in better glycemic control in patients with
Type 2 diabetes. This study was designed to assess the efficacy and safety of metformin
without vildagliptine (M without V)) and metformin with vildagliptine (M with V)in type 2 diabetic
patients on blood glucose and renal function. During eight months study period, 600 prescription
(Diabetic Books prescription and new patients initial form prescription) of patients suffering from
diabetes mellitus were analyzed from BIRDEM, Shahabag, Dhaka, Bangladesh. Patients suffering from Type 2 diabetes, male or female, age ≥22 years were included in the study. The
patients were prescribed Metformin with and without vildagliptin and also other combination
drugs for the treatment of diabetes. The present study shows that the fasting blood glucose of
the patients of M without V was 8.838 ± 2.145 mmol/L and M with V was 9.231 ± 3.475 mmol/L.
The difference was not statistically significant (p=0.8504). The blood glucose level after 2 hours
breakfast (ABF) was 12.81 ± 2.942 mmol/L in M without V group and 12.02 ± 4.315 mmol/L in M
with V group (p=0.022). The creatinine value of M without V group was 1.075 ± 0.92 mg/dl and
M with V was 1.011±0.246. The difference between the group is not statistically significant
(p=0.507). Metformin with and without Vildagliptin effectively control fasting blood glucose level
in type 2 diabetes patients. The blood glucose level after 2 hour breakfast is better controlled by
Metformin with Vildagliptin. Metformin with and without Vildagliptin has no significant effect on
creatinine level. Further study is needed with a large sample size to determine the efficacy and
safety of combination Metformin and Vildagliptin in type 2 diabetes patients.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Masters of Pharmacy (M.Pharm) in East West University, Dhaka, Bangladesh.